Endra Life Sciences announces the issuance of three new patents

Endra Life Sciences announces the issuance of three new patents, including one in the U.S., one in China and one in Europe. ENDRA’s intellectual property portfolio now includes 74 issued patents worldwide providing protection for the TAEUS system with its novel thermoacoustic technology. These patents protect novel innovations integral to the TAEUS system, ensuring maximum radiofrequency energy absorption, minimized signal noise and precise temperature monitoring during surgical procedures and thermal ablation. With the ability to accurately monitor temperature changes during thermal therapies, clinicians can, for example, optimize treatment parameters to minimize damage to healthy tissue while effectively targeting cancerous cells, leading to better therapeutic outcomes and reduced side effects. “We are proud of our growing patent estate, which is particularly impressive for a company of our size. These newly issued patents reinforce ENDRA’s commitment to advancing state-of-the-art thermoacoustic systems, and expand the horizons for our novel TAEUS(R) technology to address unmet clinical needs,” commented ENDRA’s Chief Technology Officer Michael Thornton. “We remain committed to fortifying our intellectual property to safeguard our technology in key global markets, deploying a robust portfolio that now encompasses 74 granted patents.”